Sialic acid content of tissue-specific gp96 and its potential role in modulating gp96-macrophage interactions

Glycobiology

Volumn 19, Issue 12, 2009, Pages 1427-1435

  Suriano, Robert ^a   Ghosh, Salil K ^a,b   Chaudhuri, Devyani ^a,c   Mittelman, Abraham ^a   Banerjee, Asesh ^a   Tiwari, Raj K ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Cancer; Gp96; Heat shock proteins; HPAE PAD; Sialic acid

Indexed keywords

GLYCOPROTEIN GP 96; SIALIC ACID;

ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; RAT;

ANIMALS; CELL COMMUNICATION; CELLS, CULTURED; CYTOKINES; GLYCOSYLATION; HUMANS; MACROPHAGES; MEMBRANE GLYCOPROTEINS; N-ACETYLNEURAMINIC ACID; NEOPLASMS; POLYSACCHARIDES; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 71049166701     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwp096     Document Type: Article

References (50)

1. Avidan A, Perlmutter M, Tal S, Oraki O, Kapp T, Krelin Y, Elkabets M, Dotan S, Apte RN, Lichtenstein RG. 2009. Differences in the sialylation patterns of membrane stress proteins in chemical carcinogen-induced tumors developed in BALB/c and IL-1α deficient mice. Glycoconj J. doi:10.1007/s10719-009-9238-9.
2. Babal P, Janega P, Cerna A, Kholova I, Brabencova E. 2006. Neoplastic transformation of the thyroid gland is accompanied by changes in cellular sialylation. Acta Histochem. 108:133-140.
3. Basu S, Binder R, Ramalingam T, Srivastava PK. 2001. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity. 14:303-313.
4. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. 2000. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway. Int Immunol. 12:1539-1546.
5. Berwin B, Hart JP, Rice S, Gass C, Pizzo AV, Post SR, Nicchitta CV. 2003. Scavenger receptor-A mediates gp96/grp94 and calreticulin internalization by antigen-presenting cells. EMBO J. 22:6127-6136.
6. Berwin B, Nicchitta CV. 2001. To find the road traveled to tumor immunity: The trafficking itineraries of molecular chaperones in antigen-presenting cells. Traffic. 2:690-697.
7. Binder RJ, Han DH, Srivastava PK. 2000a. CD91: A receptor for heat shock protein gp96. Nat Immunol. 1:151-155.
8. Binder R, Han DK, Srivastava PK. 2000b. CD91: A receptor for heat shock protein gp96. Nat Immunol. 2:151-155.
9. Binder RJ, Srivastava PK. 2004. Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc Natl Acad Sci USA 101:6128-6133.
10. Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S, Udono H, Srivastava PK. 1997. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med. 186:1315-1322.
11. Buchner J. 1999. Hsp90 & Co. - A holding for folding. Trends Biochem Sci 24:136-141.
12. Bukau B, Weissman J, Horwich A. 2006. Molecular chaperones and protein quality control. Cell. 125:443-451.
13. Cala SE. 2000. Grp94 hyperglycosylation and phosphorylation in Sf21 cells. Biochim Biophys Acta. 1496:296-310.
14. Ciocca DR, Frayssinet P, Cuello-Carrión FD. 2007. A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients. Cell Stress Chaperones. 12:33-43.
15. De Filippo A, Binder RJ, Camisaschi C, Beretta V, Arienti F,Villa A, Della Mina P, Parmiani G, Rivoltini L, Castelli C. 2008. Human Plasmacytoid dendritic cells interact with gp96 via CD91 and regulate inflammatory responses. J Immunol. 181:6525-6535.
16. Hart GH. 1992. Glycosylation. Curr Opin Cell Biol. 4:1017-1023.
17. Helenius A, Aebi M. 2001. Intracellular functions of N-linked glycans. Science. 291:2364-2369.
18. Huang QQ, Sobkoviak R, Jockheck-Clark AR, Shi B, Mandelin AM II, Tal PP, Haines KG III, Nicchitta CV, Pope RM. 2009. Heat shock protein 96 is elevated in rheumatoid arthritis and activates macrophages primarily via TLR2 signaling. J Immunol. 182:4965-4973.
19. Kaneko Y, Nimmerjhan F, Ravetch JV. 2006. Anti-inflammatory activity of immunoglobulin G resulting from sialylation. Science. 313:670-673.
20. Kodama S, Tsujimoto M, Tsuruoka N, Sugo T, Endo T, Kobata A. 1993. Role of sugar chains in the in vitro activity of recombinant human interleukin 5. Eur J Biochem. 211:903-908.
21. Le Marer R, Stehelin D. 1995. High alpha-2,6-sialylation of N acetyllactosamine sequences in ras-transformed rat fibroblasts correlates with high invasive potential. Glycobiology. 5:219-226.
22. Lin S, Kemmner W, Grigull S, Schlag PM. 2002. Cell surface alpha 2,6 sialylation affects adhesion of breast carcinoma cells. Exp Cell Res 276:101-110.
23. Maki RG, Livingston PO, Lewis JJ, Janetzki S, Klimstra D, Desantis D, Srivastava PK, Brennan MF. 2007. A phase I study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci. 52:1964-1972.
24. Maki RG, Old LJ, Srivastava PK. 1990. Human homologue of murine tumor rejection antigen gp96: 5′-regulatory and coding regions and relationship to stressinduced proteins. Proc Natl Acad Sci USA. 87:5658-5662.
25. Mazzarella RA, Green M. 1987. ERp99, an abundant, conserved glycoprotein of the endoplasmic reticulum, is homologous to the 90-kDa heat shock protein (hsp90) and the 94-kDa glucose regulated protein (GRP94). J Biol Chem. 262:8875-8883.
26. Miller RL, Collawn JF Jr, Fish WW. 1982. Purification and macromolecular properties of a sialic acid-specific lectin from the slug Limax flavus. J Biol Chem. 257:7574-7580.
27. Müller MR, Pfannes SD, Ayoub M, Hoffmann P, Bessler WG, Mittenbühler K. 2001. Immunostimulation by the synthetic lipopeptide P3CSK4: TLR4-independent activation of the ERK1/2 signal transduction pathway in macrophages. Immunology. 103:49-60.
28. Nalivaeva NN, Turner AJ. 2001. Post-translational modifications of proteins: Acetylcholnesterase as a model system. Proteomics. 1:735-747.
29. Nicchitta CV, Carrick DM, Baker-LePain JC. 2004. The messenger and the message: Gp96 (grp94)-peptide interactions in cellular immunity. Cell Stress Chaperones. 9:325-331.
30. Orntoft TF, Vestergaard EM. 1999. Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis. 20:362-371.
31. Reed RC, Berwin B, Baker JP, Nicchitta CV. 2003. Grp94/gp96 elicits ERK activation in murine macrophages. J Biol Chem. 278:31853-31860.
32. Rohrer JS, Thayer J, Weitzhandler M, Avdalovic N. 1998. Analysis of N acetylneuraminic acid contents pf glycoproteins by high-pH anion exchange chromatography with pulsed amperometric detection (HAPEC-/PAD). Glycobiology. 8:35-43.
33. Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR, Bellis SL. 2005. Hypersialylation of β1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res. 65:4645-4652.
34. Shin MS, Park WS, Kim SY, Kim HS, Kang SJ, Song KY, Park JY, Dong SM, Pi JH, Oh RR, et al. 1999. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol. 154:1785-1791.
35. Srivastava PK. 1997. Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens. Methods. 12:165-171.
36. Srivastava PK. 2006. Therapeutic cancer vaccines. Curr Opin Immunol 18:201-205.
37. Srivastava PK, DeLeo AB, Old LJ. 1986. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci. 83:3407-3411.
38. Srivastava PK, Maki RG. 1991. Stress-induced proteins in immune response to cancer. Curr Top Microbiol Immunol. 167:109-123.
39. Suriano R, Ghosh SK, Ashok BT, Mittelman A, Chen Y, Banerjee A, Tiwari RK. 2005. Differences in glycosylation patterns of heat shock protein, gp96: Implications for prostate cancer preventation. Cancer Res. 65:6466-6475.
40. Suto R, Srivastava PK. 1995. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 69:1585-1588.
41. Testori A, Richads J, Whitman E, Mann GB, Lutzky J, Camacho L, Parmiani G, Tosti G, Kirkwood JM, Hoos A, et al. C-100-21 Study Group. 2008. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 study group. J Clin Oncol. 26:955-962.
42. Vabulas RM, Braedel S, Hilf N, Singh-Jasuja H, Herter S, Ahmed-Nejad P, Kirschning CJ, Da Costa C, Rammensee HG, Wagner H, et al. 2002. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem 277:20847-20853.
43. Varki A. 1997. Sialic acids as ligands in recognition phenomena. FASEB J. 248-255.
44. Varki A. 2001. N-Glycolylneuraminic acid deficiency in humans. Biochime. 83:615-622.
45. Wang XH, Qin Y, Hu MH, Xie Y. 2005. Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes. Cancer Immunol Immunother 54:971-980.
46. Warger T, Hilf N, Rechtsteiner G, Haselmayer P, Carrick DM, Jonuleit H, von Landenberg P, Rammensee HG, Nicchitta CV, Radsak MP, et al. 2006. Interaction of TLR-2 and TLR-4 ligands with the N-terminal domain of gp96 amplifies innate and adaptive immune responses. J Biol Chem. 10:2-18.
47. Yang Y, Li Z. 2005. Roles of heat shock protein gp96 in ER quality control: Redundant or unique function? Mol Cell. 20:173-182.
48. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H. 2006. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 26:174-179.
49. Zabrecky JR, Sawlivich W. 2004. Purification of the heat shock protein, gp96, from natural sources. Methods. 32:3-6.
50. Zhu Y, Srivantana U, Ullah A, Gagneja H, Berenson CS, Lance P. 2001. Suppression of a sialyltransferase by antisense DNA reduces invasiveness of human colon cancer cells in vitro. Biochim Biophys Acta. 1536:219-226.